Literature DB >> 25902926

Isavuconazonium: first global approval.

Paul L McCormack1.   

Abstract

Isavuconazonium (Cresemba®) is a water-soluble prodrug of the triazole antifungal isavuconazole (BAL 4815), a 14-α-demethylase inhibitor, under development by Basilea Pharmaceutica International Ltd and Astellas Pharma Inc. Isavuconazonium, in both its intravenous and oral formulations, was approved for the treatment of invasive aspergillosis and invasive mucormycosis (formerly termed zygomycosis) in the US in March 2015. Isavuconazonium is under regulatory review in the EU for invasive aspergillosis and mucormycosis. It is also under phase III development worldwide for the treatment of invasive candidiasis and candidaemia. This article summarizes the milestones in the development of isavuconazonium leading to the first approval for invasive aspergillosis and mucormycosis.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25902926     DOI： 10.1007/s40265-015-0398-6

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  12 in total

Review 1.  Isavuconazole: a comprehensive review of spectrum of activity of a new triazole.

Authors:  George R Thompson; Nathan P Wiederhold
Journal:  Mycopathologia       Date:  2010-06-05       Impact factor: 2.574

2.  Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model.

Authors:  Alexander J Lepak; Karen Marchillo; Jamie VanHecker; Daniel Diekema; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2013-09-03       Impact factor: 5.191

3.  Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557.

Authors:  A Schmitt-Hoffmann; B Roos; J Spickermann; M Heep; E Peterfaí; D J Edwards; K Stoeckel
Journal:  Antimicrob Agents Chemother       Date:  2009-08-10       Impact factor: 5.191

4.  Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect.

Authors:  Peter A Warn; Andrew Sharp; Arvind Parmar; Jayesh Majithiya; David W Denning; William W Hope
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

5.  Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus.

Authors:  Alexander J Lepak; Karen Marchillo; Jamie Vanhecker; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2013-10-07       Impact factor: 5.191

6.  Isavuconazole therapy protects immunosuppressed mice from mucormycosis.

Authors:  Guanpingsheng Luo; Teclegiorgis Gebremariam; Hongkyu Lee; John E Edwards; Laura Kovanda; Ashraf S Ibrahim
Journal:  Antimicrob Agents Chemother       Date:  2014-02-03       Impact factor: 5.191

7.  Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei.

Authors:  J Majithiya; A Sharp; A Parmar; D W Denning; P A Warn
Journal:  J Antimicrob Chemother       Date:  2008-11-13       Impact factor: 5.790

8.  Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers.

Authors:  Anne Schmitt-Hoffmann; Brigitte Roos; Markus Heep; Michael Schleimer; Erhard Weidekamm; Tom Brown; Michael Roehrle; Christoph Beglinger
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.938

9.  Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers.

Authors:  Anne Schmitt-Hoffmann; Brigitte Roos; Jürgen Maares; Markus Heep; Jochen Spickerman; Erhard Weidekamm; Tom Brown; Michael Roehrle
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.938

Review 10.  Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections.

Authors:  Diego R Falci; Alessandro C Pasqualotto
Journal:  Infect Drug Resist       Date:  2013-10-22       Impact factor: 4.003
View more
  9 in total

Review 1.  Prophylactic Measures During Induction for Acute Myeloid Leukemia.

Authors:  Matthew W McCarthy; Thomas J Walsh
Journal:  Curr Oncol Rep       Date:  2017-03       Impact factor: 5.075

2.  The antifungal drug isavuconazole inhibits the replication of human cytomegalovirus (HCMV) and acts synergistically with anti-HCMV drugs.

Authors:  Beatrice Mercorelli; Marta Celegato; Anna Luganini; Giorgio Gribaudo; Galina I Lepesheva; Arianna Loregian
Journal:  Antiviral Res       Date:  2021-03-13       Impact factor: 5.970

Review 3.  Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations.

Authors:  Suganthini Krishnan Natesan; Pranatharthi H Chandrasekar
Journal:  Infect Drug Resist       Date:  2016-12-07       Impact factor: 4.003

Review 4.  Cutaneous mucormycosis.

Authors:  Ana Daniela Castrejón-Pérez; Esperanza C Welsh; Ivett Miranda; Jorge Ocampo-Candiani; Oliverio Welsh
Journal:  An Bras Dermatol       Date:  2017 May-Jun       Impact factor: 1.896

Review 5.  Antifungal Therapy for Systemic Mycosis and the Nanobiotechnology Era: Improving Efficacy, Biodistribution and Toxicity.

Authors:  Ana C O Souza; Andre C Amaral
Journal:  Front Microbiol       Date:  2017-03-07       Impact factor: 5.640

Review 6.  The Fungal CYP51s: Their Functions, Structures, Related Drug Resistance, and Inhibitors.

Authors:  Jingxiang Zhang; Liping Li; Quanzhen Lv; Lan Yan; Yan Wang; Yuanying Jiang
Journal:  Front Microbiol       Date:  2019-04-24       Impact factor: 5.640

7.  Triazole resistance mediated by mutations of a conserved active site tyrosine in fungal lanosterol 14α-demethylase.

Authors:  Alia A Sagatova; Mikhail V Keniya; Rajni K Wilson; Manya Sabherwal; Joel D A Tyndall; Brian C Monk
Journal:  Sci Rep       Date:  2016-05-18       Impact factor: 4.379

Review 8.  Fungal diseases: could nanostructured drug delivery systems be a novel paradigm for therapy?

Authors:  Aline Raquel Voltan; Guillermo Quindós; Kaila P Medina Alarcón; Ana Marisa Fusco-Almeida; Maria José Soares Mendes-Giannini; Marlus Chorilli
Journal:  Int J Nanomedicine       Date:  2016-08-08

9.  Tissue Distribution and Elimination of Isavuconazole following Single and Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats.

Authors:  Anne-Hortense Schmitt-Hoffmann; Kota Kato; Robert Townsend; Michael J Potchoiba; William W Hope; David Andes; Jochen Spickermann; Marlowe J Schneidkraut
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.